The Clinical Desire for Pressurized Intraperitoneal Aerosol Chemotherapy in South Korea: An Electronic Survey-based Study

Anticancer Res. 2022 Jan;42(1):363-371. doi: 10.21873/anticanres.15494.


Background/aim: To evaluate the clinical desire for pressurized intraperitoneal aerosol chemotherapy (PIPAC) in South Korea.

Patients and methods: We performed an online survey on surgical oncologists between November and December 2019 using a questionnaire consisting of 20 questions.

Results: A total of 164 respondents answered the questionnaire. Among those specialized in ovarian cancer, pseudomyxoma peritonei, and malignant mesothelioma 41.7-50% preferred PIPAC for the curative treatment of primary diseases, whereas 32.7-33.3% majoring in colorectal and hepatobiliary cancers chose it for the palliative treatment of recurrent diseases. Furthermore, 66.7-95.2% considered PIPAC appropriate for the cancers they specialized in, and 76-78.7% expected a treatment response of more than 50% and considered grade 1 or 2 complications acceptable. Most respondents answered the reasonable costs to purchase and implement PIPAC once at between 1,000,000-5,000,000 South Korean Won (KRW).

Conclusion: Most Korean surgical oncologists expected relatively high tumor response rates with minor toxicities through the repeated implementation of PIPAC.

Keywords: Pressurized intraperitoneal aerosol chemotherapy; clinical desire; cost; peritoneal metastasis; prerequisite; survey.

MeSH terms

  • Aerosols / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cisplatin / therapeutic use
  • Costs and Cost Analysis
  • Doxorubicin / therapeutic use
  • Female
  • Humans
  • Infusions, Parenteral / methods*
  • Male
  • Mesothelioma, Malignant / drug therapy
  • Mesothelioma, Malignant / pathology
  • Mesothelioma, Malignant / surgery*
  • Neoplasm Metastasis
  • Oncologists / psychology*
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / surgery*
  • Oxaliplatin / therapeutic use
  • Peritoneal Neoplasms / drug therapy
  • Peritoneal Neoplasms / pathology
  • Peritoneal Neoplasms / surgery
  • Pseudomyxoma Peritonei / drug therapy
  • Pseudomyxoma Peritonei / pathology
  • Pseudomyxoma Peritonei / surgery*
  • Surveys and Questionnaires
  • Treatment Outcome


  • Aerosols
  • Antineoplastic Agents
  • Oxaliplatin
  • Doxorubicin
  • Cisplatin